{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:26:34Z","timestamp":1791505594007,"version":"4.3.4"},"reference-count":55,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Med Ethics"],"accepted":{"date-parts":[[2023,5,19]]},"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:p>Psychedelic treatments, particularly 3,4-methylenedioxymethamphetamine (MDMA)-assisted and psilocybin-assisted therapies, have recently seen renewed interest in their clinical potential to treat various mental health conditions. Clinical trials for both MDMA-assisted and psilocybin-assisted therapies have shown to be highly efficacious for post-traumatic stress disorder and major depression. Recent research trials for psychedelic-assisted therapies (PAT) have demonstrated that although they are resource-intensive, their effects are rapid-acting, durable and cost-effective. These results have generated enthusiasm among researchers seeking to investigate psychedelic therapies in active-duty service members of the US military, particularly those with treatment refractory mental health conditions. At the same time, psychedelics remain in early stages of clinical investigation, have not yet achieved regulatory approval for general clinical use and may confer unique psychological and neurobiological effects that could raise novel ethical considerations when treating active-duty service members. Should psychedelics achieve regulatory approval, military relevant considerations may include issues of access to these treatments, appropriate procedures for informed consent, confidentiality standards, and possible unanticipated mental health risks and other psychological sequelae. A service member\u2019s deployability, as well as their ability to return to full military duty following PAT, may also be of unique concern. The authors argue that MDMA-assisted therapy currently represents a promising treatment that should be more rapidly investigated as a clinical therapy for service members while still taking a measured approach that accounts for the many military-specific uncertainties that remain.<\/jats:p>","DOI":"10.1136\/jme-2023-108943","type":"journal-article","created":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T17:20:32Z","timestamp":1685467232000},"page":"258-262","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Ethical considerations for psychedelic-assisted therapy in military clinical settings"],"prefix":"10.1136","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1140-4257","authenticated-orcid":false,"given":"Scott","family":"Hoener","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Wolfgang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Nissan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund","family":"Howe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,5,30]]},"reference":[{"key":"2024052219533633000_50.4.258.1","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-018-1590-5","article-title":"Factors associated with persistent Posttraumatic stress disorder among U.S. military service members and veterans","volume":"18","author":"Armenta","year":"2018","journal-title":"BMC Psychiatry"},{"key":"2024052219533633000_50.4.258.2","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.21m14116","article-title":"The economic burden of Posttraumatic stress disorder in the United States from a societal perspective","volume":"83","author":"Davis","year":"2022","journal-title":"J Clin Psychiatry"},{"key":"2024052219533633000_50.4.258.3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.8370"},{"key":"2024052219533633000_50.4.258.4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1037\/tra0000062","article-title":"Time course of treatment dropout in cognitive-behavioral therapies for posttraumatic stress disorder","volume":"8","author":"Gutner","year":"2016","journal-title":"Psychol Trauma"},{"key":"2024052219533633000_50.4.258.5","unstructured":"Jeffreys M . Clinician\u2019s guide to medications for PTSD. 2009. Available: http:\/\/www.ptsd.va.gov\/professional\/treatment\/overview\/clinicians-guide-to-medications-for-ptsd.asp [Accessed 13 Dec 2020]."},{"key":"2024052219533633000_50.4.258.6","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat Med"},{"key":"2024052219533633000_50.4.258.7","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S2215-0366(18)30135-4","article-title":"3,4-methylenedioxymethamphetamine (MDMA)-Assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial","volume":"5","author":"Mithoefer","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"2024052219533633000_50.4.258.8","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-019-05249-5"},{"key":"2024052219533633000_50.4.258.9","doi-asserted-by":"publisher","DOI":"10.1177\/0269881118806297"},{"key":"2024052219533633000_50.4.258.10","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of Psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"2024052219533633000_50.4.258.11","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-017-4771-x"},{"key":"2024052219533633000_50.4.258.12","doi-asserted-by":"publisher","DOI":"10.1177\/02698811211073759"},{"key":"2024052219533633000_50.4.258.13","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following Psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"2024052219533633000_50.4.258.14","doi-asserted-by":"publisher","DOI":"10.3109\/00952990.2016.1170135"},{"key":"2024052219533633000_50.4.258.15","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"2024052219533633000_50.4.258.16","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-020-05548-2"},{"key":"2024052219533633000_50.4.258.17","doi-asserted-by":"publisher","DOI":"10.1177\/0269881108093587"},{"key":"2024052219533633000_50.4.258.18","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2019.00650","article-title":"Breakthrough for trauma treatment: safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline","volume":"10","author":"Feduccia","year":"2019","journal-title":"Front Psychiatry"},{"key":"2024052219533633000_50.4.258.19","doi-asserted-by":"crossref","unstructured":"Mitchell JM . A Psychedelic May Soon Go to the FDA for Approval to Treat Trauma. Scientific American, 2022: 56\u201361.","DOI":"10.1038\/scientificamerican0222-56"},{"key":"2024052219533633000_50.4.258.20","unstructured":"Doblin R . Statement: Biden administration preparing for potential FDA approval of MDMA-assisted therapy for PTSD. 2022. Available: https:\/\/maps.org\/2022\/07\/27\/statement-biden-administration-preparing-for-potential-fda-approval-of-mdma-assisted-therapy-for-ptsd\/"},{"key":"2024052219533633000_50.4.258.21","unstructured":"Policy and position statements of conversion therapy. 2018. Available: https:\/\/www.hrc.org\/resources\/policy-and-position-statements-on-conversion-therapy [Accessed 20 Apr 2022]."},{"key":"2024052219533633000_50.4.258.22","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfr088"},{"key":"2024052219533633000_50.4.258.23","unstructured":"Lee MA , Shlain B . Acid Dreams: The Complete Social History of LSD; The CIA, the Sixties, and Beyond. New York, NY: Grove Press, 1985."},{"key":"2024052219533633000_50.4.258.24","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1007\/s13311-017-0542-y","article-title":"Potential therapeutic effects of Psilocybin","volume":"14","author":"Johnson","year":"2017","journal-title":"Neurotherapeutics"},{"key":"2024052219533633000_50.4.258.25","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12904"},{"key":"2024052219533633000_50.4.258.26","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116662634"},{"key":"2024052219533633000_50.4.258.27","unstructured":"Prior positive results confirmed in MAPS sponsored, Philanthropy funded phase 3 trial; 2023."},{"key":"2024052219533633000_50.4.258.28","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/s41386-019-0569-3","article-title":"Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects","volume":"45","author":"Holze","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"2024052219533633000_50.4.258.29","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.557"},{"key":"2024052219533633000_50.4.258.30","unstructured":"Project Mkultra, the CIA\u2019s program of Research in behavioral modification: joint hearing before the select Committee on intelligence and the subcommittee on health and scientific research of the Committee on human resources. Washington, DC; 1977."},{"key":"2024052219533633000_50.4.258.31","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1353\/pbm.2016.0019","article-title":"Acid Brothers: Henry Beecher, Timothy Leary, and the Psychedelic of the century","volume":"59","author":"Moreno","year":"2016","journal-title":"Perspect Biol Med"},{"key":"2024052219533633000_50.4.258.32","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1177\/0957154X17717678","article-title":"LSD experiments by the United States Army","volume":"28","author":"Ross","year":"2017","journal-title":"Hist Psychiatry"},{"key":"2024052219533633000_50.4.258.33","doi-asserted-by":"crossref","first-page":"e527","DOI":"10.1093\/milmed\/usaa007","article-title":"A code of ethics for military medicine","volume":"185","author":"Thomas","year":"2020","journal-title":"Mil Med"},{"key":"2024052219533633000_50.4.258.34","unstructured":"Protection of human subjects and adherence to ethical standards in Dod conducted and supported research. D.o. Defense; 2020."},{"key":"2024052219533633000_50.4.258.35","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.16230"},{"key":"2024052219533633000_50.4.258.36","unstructured":"DoD civilian employee drug-free workplace program. D.o. Defense; 2012."},{"key":"2024052219533633000_50.4.258.37","doi-asserted-by":"crossref","unstructured":"Ponomarenko P , Seragnoli F , Calder A , et al . Can Psychedelics enhance group psychotherapy? A discussion on the therapeutic factors. J Psychopharmacol 2023:2698811231155117. doi:10.1177\/02698811231155117","DOI":"10.1177\/02698811231155117"},{"key":"2024052219533633000_50.4.258.38","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1176\/appi.ajp.22010073","article-title":"A case of prolonged mania, psychosis, and severe depression after Psilocybin use: implications of increased Psychedelic drug availability","volume":"179","author":"Barber","year":"2022","journal-title":"Am J Psychiatry"},{"key":"2024052219533633000_50.4.258.39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063972","article-title":"Psychedelics and mental health: a population study","volume":"8","author":"Krebs","year":"2013","journal-title":"PLoS One"},{"key":"2024052219533633000_50.4.258.40","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-016-1066-4","article-title":"Psychosis associated with acute recreational drug toxicity: a European case series","volume":"16","author":"Vallersnes","year":"2016","journal-title":"BMC Psychiatry"},{"key":"2024052219533633000_50.4.258.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2017.12.040"},{"key":"2024052219533633000_50.4.258.42","doi-asserted-by":"crossref","DOI":"10.1093\/nc\/niz013","article-title":"The ethics of Psychedelic research in disorders of consciousness","volume":"2019","author":"Peterson","year":"2019","journal-title":"Neurosci Conscious"},{"key":"2024052219533633000_50.4.258.43","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1021\/acsptsci.1c00020","article-title":"Acute and sustained reductions in loss of meaning and suicidal Ideation following Psilocybin-assisted psychotherapy for psychiatric and existential distress in life-threatening cancer","volume":"4","author":"Ross","year":"2021","journal-title":"ACS Pharmacol Transl Sci"},{"key":"2024052219533633000_50.4.258.44","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116675513"},{"key":"2024052219533633000_50.4.258.45","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1177\/0269881120926673","article-title":"Acute effects of MDMA on trust, cooperative behaviour and empathy: a double-blind, placebo-controlled experiment","volume":"35","author":"Borissova","year":"2021","journal-title":"J Psychopharmacol"},{"key":"2024052219533633000_50.4.258.46","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1177\/0269881117711712","article-title":"Therapeutic effect of increased openness: investigating mechanism of action in MDMA-assisted psychotherapy","volume":"31","author":"Wagner","year":"2017","journal-title":"J Psychopharmacol"},{"key":"2024052219533633000_50.4.258.47","unstructured":"Albayrak E . Microdosing: Improving Performance Enhancement in Intelligence Analysis. Marine Corps Gazette, 2019."},{"key":"2024052219533633000_50.4.258.48","doi-asserted-by":"publisher","DOI":"10.1136\/medethics-2020-106070"},{"key":"2024052219533633000_50.4.258.49","doi-asserted-by":"publisher","DOI":"10.1197\/j.aem.2005.05.037"},{"key":"2024052219533633000_50.4.258.50","doi-asserted-by":"publisher","DOI":"10.1136\/jramc-2018-001023"},{"key":"2024052219533633000_50.4.258.51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199384","article-title":"Oxytocin receptor gene variations and socio-emotional effects of MDMA: a pooled analysis of controlled studies in healthy subjects","volume":"13","author":"Vizeli","year":"2018","journal-title":"PLoS One"},{"key":"2024052219533633000_50.4.258.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2013.12.015"},{"key":"2024052219533633000_50.4.258.53","unstructured":"Command notification requirements to dispel stigma in providing mental health care to service members. Washington, DC D.o. Defense; 2011."},{"key":"2024052219533633000_50.4.258.54","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/bsl.2370070304","article-title":"Confidentiality in the military","volume":"7","author":"Howe","year":"1989","journal-title":"Behav Sci Law"},{"key":"2024052219533633000_50.4.258.55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012412","article-title":"Psychometric evaluation of the altered States of consciousness rating scale (OAV)","volume":"5","author":"Studerus","year":"2010","journal-title":"PLoS One"}],"container-title":["Journal of Medical Ethics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jme-2023-108943","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T02:55:59Z","timestamp":1716432959000},"score":1,"resource":{"primary":{"URL":"https:\/\/jme.bmj.com\/lookup\/doi\/10.1136\/jme-2023-108943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,30]]},"references-count":55,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,3,20]]},"published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1136\/jme-2023-108943"],"URL":"https:\/\/doi.org\/10.1136\/jme-2023-108943","relation":{},"ISSN":["0306-6800","1473-4257"],"issn-type":[{"value":"0306-6800","type":"print"},{"value":"1473-4257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,30]]}}}